Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHeldmann, F.-
dc.contributor.authorBrandt, J.-
dc.contributor.authorvan der Horst-Bruinsma, I. E.-
dc.contributor.authorLandewe, R.-
dc.contributor.authorSieper, J.-
dc.contributor.authorBurmester, G. R.-
dc.contributor.authorvan den Bosch, F.-
dc.contributor.authorde Vlam, K.-
dc.contributor.authorGEUSENS, Piet-
dc.contributor.authorGaston, H.-
dc.contributor.authorSchewe, S.-
dc.contributor.authorAppelboom, T.-
dc.contributor.authorEmery, P.-
dc.contributor.authorDougados, M.-
dc.contributor.authorLeirisalo-Repo, M.-
dc.contributor.authorBreban, M.-
dc.contributor.authorListing, J.-
dc.contributor.authorBraun, J.-
dc.identifier.citationCLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 29 (4), p. 672-680-
dc.description.abstractObjectives To study the long-term efficacy and safety of treatment with infliximab in patients with ankylosing spondylitis (AS) in a real life setting. Methods AS patients from 6 European countries who had finished the 2-year trial ASSERT were invited to participate in the open-label investigator-driven study EASIC. At baseline, 2 groups were formed: patients of group 1 had not been treated with infliximab after ASSERT, while those of group 2 had continuously received it. Patients of group I were further subdivided in group I a: patients with a relapse and 1b: in remission. All patients of group la and 2 continuously received infliximab for 96 weeks, mean dose 5 mg/kg, intervals 6-8 weeks. Patients of group 1b were also treated in case of relapse. Results A total of 103/149 patients (69%) were included in EASIC, 1.3 +/- 0.9 years after the end of ASSERT: 9 in group 1a, 5 in group 1b and 89 in group 2. Most patients were male (83%), mean age 44 years. Most patients of group 2 completed the trial (86%) vs. only 5 of group 1 (33%) mostly due to allergic reactions after readministration of infliximab. In total, there were 22 drop-outs due to 6 adverse events, 4 lack of efficacy, 3 planned pregnancy. All standard assessments indicated beneficial values over time, at week 96 significantly better than at baseline of ASSERT. Conclusion The majority, of patients were continuously and successfully treated with infliximab for 5 years, whereas discontinuation and reintroduction of therapy was less satisfactory due to the frequent occurrence of hypersensitivity reactions. Anti-TNF therapy with infliximab proved to be effective and safe on a long-term basis.-
dc.description.sponsorshipCentocor provided financial support for the conduction of this investigator-initiated study. The authors declare that they have no financial competing interests associated with this research. G.R. Burmester has received honoraria for consultations and lectures from Essex Germany and MSD Germany; F. van den Bosch is a member of speakers' bureau for Schering-Plough; P. Emery has provided consultation to Abbott, BMS, MSD, Pfizer, Roche and UCB; M. Dougados has received honoraria for consultations and grant support from Abbott, Centocor, Pfizer, Schering-Plough and UCB; M. Lerisalo-Repo has received honoraria for consultations from MSD and Schering-Plough; M. Breban has received honoraria from Abbott and. support from Pfizer and Schering-Plough.-
dc.subject.otherankylosing spondylitis; anti-TNF; infliximab-
dc.titleThe European Ankylosing Spondylitis Infliximab Cohort (EASIC): a European multicentre study of long-term outcomes in patients with ankylosing spondylitis treated with infliximab-
dc.typeJournal Contribution-
dc.description.notes[Heldmann, F.; Braun, J.] Rheumazentrum Ruhrgebiet, D-44652 Herne, Germany. [Brandt, J.] Rheumapraxis Steglitz Charite, Berlin, Germany. [van der Horst-Bruinsma, I. E.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands. [Landewe, R.] Acad Ziekenhuis Maastricht, Maastricht, Netherlands. [Sieper, J.] Charite Campus Benjamin Franklin, Berlin, Germany. [Burmester, G. R.] Charite Univ Med Berlin, Berlin, Germany. [van den Bosch, F.] Univ Ziekenhuis Ghent, Ghent, Belgium. [de Vlam, K.] Univ Hosp Leuven, Louvain, Belgium. [Geusens, P.] Univ Hasselt, Genk, Belgium. [Gaston, H.] Univ Cambridge, Cambridge CB2 1TN, England. [Schewe, S.] Klinikum Univ Munich, Munich, Germany. [Appelboom, T.] Hop Erasme Brussels, Brussels, Belgium. [Emery, P.] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England. [Dougados, M.] Hop Cochin Paris, Paris, France. [Leirisalo-Repo, M.] Univ Cent Hosp Helsinki, Helsinki, Finland. [Breban, M.] Hop Ambroise Pare, Boulogne, France. [Listing, J.] Deutsch Rheumaforschungszentrum Berlin, Berlin, Germany.
item.fulltextNo Fulltext-
item.accessRightsClosed Access-
item.contributorGEUSENS, Piet-
item.contributorDougados, M.-
item.contributorLandewe, R.-
item.contributorAppelboom, T.-
item.contributorLeirisalo-Repo, M.-
item.contributorvan der Horst-Bruinsma, I. E.-
item.contributorListing, J.-
item.contributorHeldmann, F.-
item.contributorEmery, P.-
item.contributorGaston, H.-
item.contributorBreban, M.-
item.contributorBrandt, J.-
item.contributorSieper, J.-
item.contributorvan den Bosch, F.-
item.contributorBurmester, G. R.-
item.contributorde Vlam, K.-
item.contributorBraun, J.-
item.contributorSchewe, S.-
item.fullcitationHeldmann, F.; Brandt, J.; van der Horst-Bruinsma, I. E.; Landewe, R.; Sieper, J.; Burmester, G. R.; van den Bosch, F.; de Vlam, K.; GEUSENS, Piet; Gaston, H.; Schewe, S.; Appelboom, T.; Emery, P.; Dougados, M.; Leirisalo-Repo, M.; Breban, M.; Listing, J. & Braun, J. (2011) The European Ankylosing Spondylitis Infliximab Cohort (EASIC): a European multicentre study of long-term outcomes in patients with ankylosing spondylitis treated with infliximab. In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 29 (4), p. 672-680.-
item.validationecoom 2012-
Appears in Collections:Research publications
Show simple item record


checked on Jul 1, 2022

Page view(s)

checked on Jul 3, 2022

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.